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ABSTRACT Atopic dermatitis (AD) is a common, chronic skin disease in 
children that may affect their quality of life (QoL). The aim of this study 
was to assess QoL in children in Montenegro with moderate to severe 
AD. A cross-sectional study was conducted at the Clinic of Dermatology 
and Venereology, Clinical Center of Montenegro, Podgorica, between 
January and December 2014. The study group included 200 children 
(97 boys and 103 girls) with the diagnosis of AD. The Infants’ Derma-
titis Quality of Life Index (IDQOL) and the Children’s Dermatology Life 
Quality Index (CDLQI) were used to determine QoL for 90 infants (<4 
years old) and 110 children (4-16 years old), respectively. Severity of 
disease was measured by the three-item severity (TIS) score. The mean 
scores were 14.38±5.57 for IDQOL and 18.43±4.88 for CDLQI. A positive 
correlation was observed between AD clinical severity (TIS) and all the 
items of IDQOL with Spearman’s correlation coefficient (ρ) ranging from 
0.31 to 0.74, and between AD clinical severity and all domains of CDLQI 
(ρ=0.31-0.69). The impact of AD on health-related quality of life (HRQoL) 
was more severe for younger girls, but only in some domains (IDQOL), 
and for older boys (CDLQI). The linguistically validated Serbian versions 
of both IDQOL and CDLQI questionnaires showed good internal con-
sistency with Cronbach’s alpha values of 0.88 and 0.73, respectively. In 
conclusion, our results demonstrate that AD has a great impact on QoL. 
A positive correlation between clinical severity and quality of life was 
seen.
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INTRODUCTION
Atopic dermatitis (AD) or  “eczema”  is the most com-
mon chronic inflammatory skin disease in children, with 
a prevalence of over 20% in most developed countries 
(1,2). Over the recent decade, AD prevalence in devel-
oped countries did not significantly increase or even 
decreased, whereas it continued to rise in most devel-
oping countries, especially in young children and in low 
income countries such as Africa and eastern Asia (3).
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The chronic nature of AD taken together with 
its high prevalence makes it a major public health 
problem worldwide, with great social and financial 
implications for individuals, health care systems, and 
whole societies (4-7). 
There is evidence to suggest that childhood AD 
poses a significant burden on health-related quality 
of life (HRQoL) and quality of life (QoL) of the fam-
ily unit (7-13). The impairment of QoL caused by AD 
has been shown to be greater than or equal to other 
chronic diseases of childhood, such as asthma and 
diabetes (14).
The aim of this study was to assess HRQoL in 
children with AD aged ≤16 years from Montenegro, 
Europe, and to explore the relation between HRQOL 
and gender and disease severity.
PATIENTS AND METHODS
Patients and study design
A cross-sectional study was conducted at the Clin-
ic of Dermatology and Venereology, Clinical Center of 
Montenegro (CCM), Podgorica, between January and 
December 2014. The study group included 200 chil-
dren with AD (97 boys and 103 girls) ranging from 0 
to 16 years. The Hanifin and Rajka diagnostic criteria 
for AD were used (15). 
The study was approved by the Ethics Committee 
of the CCM. Written informed consent was obtained 
from all patients. 
Instruments
Patients’ characteristics such as age, sex, age at 
onset of disease, comorbidities, and family history of 
atopic diseases were recorded by using a short ques-
tionnaire.
HRQoL was assessed by completing the Serbian 
versions of the Infant’s Dermatitis Quality of Life In-
dex (IDQOL) (16) and the Children’s Dermatology Life 
Quality Index (CDLQI) questionnaires, respectively 
(17).
The Infant’s Dermatitis Quality of Life Index 
questionnaire
This questionnaire is designed for use in infants 
with AD below the age of 4 years (18). It is self-ex-
planatory and should be completed by the child’s 
parent or guardian. IDQOL is calculated by summing 
the score of each question (0-3) resulting in a maxi-
mum of 30 and a minimum of 0. The higher the score, 
the more QoL is impaired. The severity of eczema as 
assessed by the parents is scored separately and can 
be correlated with the main questionnaire. 
The Children’s Dermatology Life Quality 
Index questionnaire
This questionnaire is designed for use in children, 
i.e. patients from age 4 to age 16. It is self explana-
tory and can be simply given to the patient who is 
asked to fill it in with the help of the child’s parent or 
guardian (19).  The total score of CDLQI is calculated 
by summing the score of the 10 questions (0-3), re-
sulting in a maximum of 30 and a minimum of 0. The 
higher the score, the more the QoL is impaired. 
Three-item severity (TIS) score
Severity of disease was measured with the three-
item severity (TIS) score (20). It is a simple scoring sys-
tem using three of the intensity items of the SCORAD 
(SCORing AD) index: erythema (redness) 0-3, edema 
0-3, and excoriations (scratches) 0-3 in one or several 
different representative areas, and it can be regarded 
as a global scoring system (21). The maximum score 
is 9. Based on the TIS score, the severity of AD can be 
classified into mild (<3), moderate (3-5), and severe 
(≥6). The mean time to assess the TIS is less than one 
minute.
Statistical analysis
Continuous variables were expressed as mean 
± standard deviation (SD), and categorical variables 
were expressed through frequency and percentage. 
To assess differences between variables, Student’s t-
test and chi-squared test were used where appropri-
ate. To verify how IDQOL and CDQOL items correlated 
with disease severity we used Spearman’s rho (ρ) cor-
relation coefficient. Nine multiple linear regression 
models were used to determine whether IDQOL and 
CDLQI scores were related to independent variables, 
such as age, sex, age at onset of disease, disease se-
verity, other atopic diseases, and family history of 
atopic diseases. A two-tailed probability value of 0.05 
or less was considered significant. All statistical analy-
ses were performed with the Statistical Package for 
the Social Sciences (SPSS), version 20.0 for Windows 
(SPSS Inc., Chicago, IL, USA).
RESULTS
Demographic and clinical characteristics of 200 
children (97 boys and 103 girls, mean age 5.23±4.35) 
with moderate to severe AD are shown on Table 1.
Girls were older, had later onset and longer dura-
tion of the disease. However, there were no signifi-
cant differences between boys and girls with regard 
to disease severity, presence of other atopic diseases 
(such as asthma, allergic rhinitis or allergic conjuncti-
vitis), and family history of atopic diseases. 
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The 10 items scores of IDQOL and 6 domains 
scores of CDLQI, differentiated according to sex are 
presented in Table 2.
The highest scoring items/domains in children 
with AD in our study were those related to the 
“child’s mood” (1.93±0.82), “itching and scratching” 
(1.91±0.71), and “problems caused by the treatment” 
(1.76±0.86) – items of the IDQOL; and “leisure time” 
(5.09±1.88), “symptoms (such as itching and soreness) 
and feelings” (4.28±1.35), and “personal relationship” 
(2.63±1.59) – domains of the CDLQI. The items of 
IDQOL, “itching and scratching”, “disturbed family ac-
tivities”, and “problems at bath time” were more prev-
alent in girls than in boys, while the opposite was true 
for all CDLQI domains, except for “leisure” where such 
differences did not reach statistical significance.
A positive correlation was observed between 
clinical severity (TIS) and all the items of IDQOL, with 
Spearman’s correlation coefficient ranging from 0.31 
to 0.74, and between total IDQOL score and its items 
(ρ=0.60-0.78). Clinical disease severity (TIS score) and 
severity assessed by parents also strongly correlated 
Table 1. Characteristics of the studied children
Characteristic Total sample 
(N=200)
Boys (N=97) Girls (N=103) P
Age, years (mean ± SD) 5.23±4.35 4.40±3.92 6.00±4.60 0.009*
Age, years at onset (mean ± SD) 2.07±2.41 1.77±2.27 2.35±2.51 0.090*
Disease duration (mean ± SD) 3.14±2.85 2.59±2.37 3.65±3.17 0.008*
Disease severity, n (%)
Moderate (TIS=3-5) 168 (84.0) 78 (80.4) 90 (87.4) 0.179†
Severe (TIS ≥6) 32(16.0) 19 (19.6) 13 (12.6)
TIS (mean ± SD) 5.40±1.42 5.40±1.62 5.39±1.22 0.946*
Other atopic disease‡, n (%) 86 (43.0) 37 (43.0) 49 (57.0) 0.178†
Family history of atopic disease‡, n (%) 146 (73) 69 (47.3) 77 (52.7) 0.564†
*t-test; +χ² test  
‡Asthma, allergic rhinitis, and/or allergic conjunctivitis 
SD: Standard deviation; TIS: Three-Item Severity score
Table 2. The Infants’ Dermatitis Quality of Life Index (IDQOL) and Children’s Dermatology Life Quality Index 
(CDLQI) domains and total scores according to sex
IDQOL (n = 90 infants) Total Boys Girls P*
Mean ± SD
Itching and scratching 1.91±0.71 1.75±0.76 2.13±0.58 0.011
Child’s mood 1.93±0.82 1.94±0.80 1.92±0.85 0.904
Time to get to sleep 1.08±0.75 1.02±0.78 1.16±0.72 0.391
Sleep disturbances 1.27±0.75 1.23±0.78 1.32±0.70 0.596
Disturbed playing 1.34±071 1.25±0.68 1.47±0.72 0.138
Disturbed family activities 1.34±0.72 1.19±0.71 1.55±0.69 0.018
Problems during meal times 1.22±0.82 1.17±0.76 1.29±0.90 0.508
Problems from treatment 1.76±0.86 1.67±0.88 1.87±0.84 0.293
Dressing problems 1.19±0.85 1.10±0.82 1.32±0.87 0.226
Problems at bath time 1.33±0.98 1.15±0.96 1.58±0.98 0.042
Total score 14.38±5.57 13.48±5.30 15.60±5.77 0.074
CDLQI (n=110 children)
Symptoms and feelings 4.28±1.35 4.62±1.34 4.05±1.32 0.027
Leisure 5.09±1.88 5.44±1.67 4.85±1.99 0.101
School or holidays 2.27±0.66 2.51±0.51 2.11±0.71 0.001
Personal relationships 2.63±1.59 3.09±1.66 2.32±1.47 0.012
Sleep 1.86±0.72 2.11±0.83 1.69±0.58 0.002
Treatment 2.28±0.62 2.47±0.50 2.15±0.67 0.009
Total score 18.43±4.88 20.24±4.88 17.17±4.49 0.001
*t-test; SD: Standard deviation
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between themselves (ρ=0.71) (Table 3).
As shown in Table 4, a positive correlation was 
found between clinical severity and all domains of 
CDLQI (ρ=0.31-0.69), as well as between total CDLQI 
scores and all its domains (ρ=0.43-0.83) (Table 4). 
The results of multiple linear regression analyses 
are shown in Table 5. 
The effect of severity (TIS score) was highly signifi-
cant for all observed domains of IDQOL and CDLQI. 
The highest values of standardized regression coef-
ficients related to severity were seen for total IDQOL 
and total CDLQI scores, following by those for “symp-
toms and feelings” and “leisure” – domains of CDLQI. 
The presence of atopic diseases other than AD was 
significantly related to “problems with treatment” 
and total IDQOL score, whereas other variables (sex, 
age, age at onset, and family history of atopic diseas-
es) were not significantly related to any of the IDQOL 
score. A weak association was seen between “symp-
toms and feelings” and “leisure” (domains of CDLQI) 
and the presence of atopic diseases in study subjects 
and their families. The effects of sex, age, and age at 
disease onset were also weak for total CDLQI score, 
and “symptoms and feelings” of CDLQI (Table 5).
All scales of both IDQOL and CDLQI question-
naires showed good internal consistency with mean 
Cronbach’s alpha coefficients of 0.88 and 0.73, re-
spectively.
DISCUSSION
To our knowledge, this is the first published study 
to investigate HRQoL in a Montenegrin sample of 
Table 3. Correlation matrix of atopic dermatitis severity and Infants’ Dermatitis Quality of Life Index (IDQOL)
IDQOL TIS
IDQOL1 IDQOL2 IDQOL3 IDQOL4 IDQOL5 IDQOL6 IDQOL7 IDQOL8 IDQOL9 IDQOL10 Total score
TIS 0.60** 0.53** 0.65** 0.31** 0.60** 0.61** 0.50** 0.40** 0.54** 0.60** 0.74**
Severity† 0.50** 0.62** 0.67** 0.39** 0.57** 0.51** 0.44** 0.42** 0.34** 0.50** 0.70** 0.71**
IDQOL
Total score 0.67** 0.68** 0.77** 0.68** 0.70** 0.66** 0.68** 0.60** 0.66** 0.78**
IDQOL10 0.38** 0.36** 0.50** 0.50** 0.44** 0.48** 0.48** 0.42** 0.73**
IDQOL9 0.32** 0.24* 0.43** 0.33** 0.35** 0.38** 0.41** 0.40**
IDQOL8 0.41** 0.40** 0.28** 0.45** 0.45** 0.11 0.26*
IDQOL7 0.40** 0.36** 0.56** 0.45** 0.39** 0.54**
IDQOL6 0.36** 0.50** 0.56** 0.37** 0.41**
IDQOL5 0.44** 0.52** 0.57** 0.50**
IDQOL4 0.41** 0.40** 0.43**
IDQOL3 0.55** 0.58**
IDQOL2 0.55**
*P< 0.05; **P< 0.01; †Assessed by parents; IDQOL1: Itching and scratching; IDQOL2: Child’s mood; IDQOL3: Time to get to sleep; 
IDQOL4: Sleep disturbances; IDQOL5: Disturbed playing; IDQOL6: Disturbed family activities; IDQOL7: Problems during meal 
times; IDQOL8: Problems from treatment; IDQOL9: Dressing problems; IDQOL10: Problems at bath time; TIS: Three-Item Se-
verity score




Leisure School or 
holidays
Personal relationships Sleep Treatment Total score
TIS 0.60** 0.53** 0.31** 0.58** 0.34** 0.37** 0.69**
CDLQI
Total score 0.79** 0.83** 0.43** 0.67** 0.65** 0.61**
Treatment 0.57** 0.49** 0.12 0.16 0.46**
Sleep 0.43** 0.45** 0.17 0.29**
Personal relationships 0.37** 0.41** 0.42**
School or holidays 0.14 0.25**
Leisure 0.61**
**P<0.01
TIS: Three-Item Severity score
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children with AD. Two questionnaires were used to 
assess QoL: the IDQOL index for infants of less than 
4 years of age and the CDLQI index for children aged 
4-16 years. Our study showed the negative effect of 
AD on HRQL. The total IDQOL and CDLQI scores were 
found to be 14.38 and 18.43, respectively, much high-
er than in all previous studies (9-13,18,22-24). These 
high scores can be explained by the fact that the most 
severe forms of AD are treated at the CCM as a tertiary 
care hospital and center of excellence for dermatol-
ogy in Montenegro. It seems reasonable that patients 
referred to a specialist would be likely to have more 
severe disease than patients treated at a general prac-
tice. All patients analyzed in the present study suffered 
from a moderate to severe form of the disease. 
As in almost all studies that have the used IDQOL 
index, we found “child’s mood” and “itching and 
scratching” to have the highest negative impacts on 
HRQoL in children affected by AD (10,13,18,22-26). 
Chronic itch in pruritic diseases such as AD is quite 
frustrating and very damaging to HRQOL. It induces 
scratching and thus worsens the condition of the 
skin, resulting in a vicious itching-scratching cycle 
(27) with consequences on the child’s mood. 
AD is a chronic remittent skin disease which re-
quires long-term treatment. Despite the positive im-
pact of topical anti-inflammatory therapy on patient 
quality of life (28), “problems caused by treatment” 
have been frequently reported (7,22), which is in ac-
cordance with our results.
We used the TIS score to assess AD severity, which 
corresponds well with the more detailed SCORAD. 
The simplicity of TIS makes it a suitable tool for re-
search studies or daily clinical practice (20,21,29). 
Our results showed a strong correlation between 
HRQoL and clinical disease severity (ρ=0.74 for IDQOL; 
ρ=0.69 for CDLQI), that is in agreement with previ-
ous studies (23-25,30,31). Correlation of IDQOL with 
clinical severity as assessed by parents were insigni-
ficantly lower (ρ=0.70 for overall IDQOL score), but 
higher than in a study by Lewis-Jones et al. (ρ=0.58) 
(18). The comparison between clinical disease sever-
ity and parent-assessed severity in the present study 
indicated a strong correlation (ρ=0.71). In opposition 
to our findings, Brazilian authors reported a discrep-
ancy between clinical and parent assessment of the 
children’s disease severity (22). 
Our study showed a significant gender difference 
in overall CDLQI score – the impact of AD on QoL was 
more severe in boys. We also found that IDQOL items 
“itching and scratching”, “disturbed family activities”, 
and “problems at bath time” had higher scores in girls, 
but we failed to find a significant difference in overall 
IDQoL score. According to Chernyshov, the impact of 
AD on QoL measured by IDQOL was more severe in 
girls (10). In contrast, several other studies did not de-
tect any significant gender difference in QoL in their 
patients (13,23,24,26). 
AD is characterized by eczematous changes in the 
epidermis, and most patients have an atopic back-
ground with past and familial histories of bronchial 
asthma, allergic rhinitis, and/or allergic conjunctivitis 
(32). In the present study, a weak significant associa-
tion between the presence of other atopic disorders 
and QoL was seen only for the total score and “treat-
ment problems” (IDQOL), and “symptoms and feel-
ings” and “leisure” (CDLQI). Ganemo et al. reported 
that AD with other concomitant atopic diseases im-
paired QoL more than AD did alone (13). In contrast, 
in two other studies no significant differences were 
observed concerning the association of QoL and oth-
er atopic disorders (23,24). 
The Serbian validated and culturally adapted 
Table 5. Standardized regression coefficients in multiple regression models of the most affected domains 











Sex ns ns ns ns ns ns ns ns -0.18**
Age, years ns ns ns ns 0.20** ns ns ns ns
Age at onset ns ns ns ns -0.19* ns ns ns ns
TIS 0.53** 0.54** 0.32** 0.76** 0.77** 0.69** 049** 0.43** 0.79**
Atopic disease† ns ns 0.32** 0.18* 0.25** 0.18* ns ns ns
Family history of 
atopic disease† 
ns ns ns ns 0.27** 0.23** ns ns 0.20**
*P<0.05; **P<0.01; †Asthma, allergic rhinitis, and/or allergic conjunctivitis
ns: non-significant; TIS: Three-Item Severity score
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versions of both IDQOL and CDLQI questionnaires 
showed good internal consistency with a Cronbach’s 
alpha values of 0.88 and 0.73, respectively. In addi-
tion, they are easy to use and can usually be complet-
ed within few minutes. 
However, the study has some limitations. First of 
all, only subjects with moderate to severe forms of AD 
were enrolled in the study. Because of that it is not 
possible to generalize the results of our study to other 
subjects in the population of Montenegro affected by 
AD. Furthermore, we had no control group so it was 
not possible to compare QoL of children affected by 
AD and other dermatological diseases.
CONCLUSION  
Our study found a strong negative impact of AD 
on patient HRQOL. Greater severity of disease was 
associated with greater impairment in HRQOL. The 
impact of AD on HRQoL was more severe for younger 
girls, but only in some domains, and for older boys. 
Establishing of the degree of QOL impairment associ-
ated with AD might help doctors improve their rela-
tionship with patients and facilitate the management 
of treatment. 
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